Ken Boda

Ken Boda, Agilent, discusses small-volume dissolution for low-dose drugs and implants, emphasizing biorelevance, USP apparatuses, and technical risks.

Nanoparticles are increasingly being used to overcome low solubility and poor permeability.

Nanoparticles are becoming more prevalent to overcome low solubility and poor permeability.